IPO Newsroom(@IPONewsroom_):AI BIOTECH ENVEDA DOUBLES VALUATION TO $2B Enveda has raised new funding led by Catalio Capital alongside Iconiq, doubling its valuation to $2 Billion. The company uses AI to discover drugs from plants and microbes and has produced 17 candidates since 2019, including pills targeting post-GLP-1 weight maintenance, atopic dermatitis and inflammatory bowel disease.

IPO Newsroom

@IPONewsroom_

Your IPO newsroom. S-1 filings, pricing updates, debut coverage, and post-IPO performance.

加入 November 2024

108 正在關注 30.1K 粉絲

IPO Newsroom@IPONewsroom_

2026.09.23 10:21

AI BIOTECH ENVEDA DOUBLES VALUATION TO $2B Enveda has raised new funding led by Catalio Capital alongside Iconiq, doubling its valuation to $2 Billion. The company uses AI to discover drugs from plants and microbes and has produced 17 candidates since 2019, including pills targeting post-GLP-1 weight maintenance, atopic dermatitis and inflammatory bowel disease.